Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction

Polat, Veli; Bozçalı, Evin; Uygun, Turgut; Opan, Selçuk; Karakaya, Osman

doi:10.1080/ac.71.2.3141849

Cited by 29 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…28 Consistent with our study, Polat and coworkers also demonstrated that NT-proBNP levels were significantly elevated in patients with HFpEF when compared with controls (p < 0.0001). 25 In our study, serum Galectin-3 has shown a positive correlation with NT-proBNP (r = 0.21, p = 0.048). Consistent with our study, Chen et al have reported a positive correlation of Galectin-3 with NT-proBNP levels (r = 0.399, p < 0.01).…”

Section: Discussionsupporting

confidence: 59%

“…24 Similar results were also observed by Polat et al, who reported that Galectin-3 levels were significantly increased in patients with HFpEF when compared with controls (p < 0.0001). 25 Zile and colleagues also demonstrated in one small series that Galectin-3 levels were significantly elevated in a cohort of patients with HFpEF. 26 Experimental studies suggest that Galectin3 is important for the development and progression of HFpEF.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction

et al. 2020

View full text Add to dashboard Cite

Background Heart failure is a complex cardiovascular disease with a variety of etiologies and heterogeneity. The N-terminal pro-B-type natriuretic peptide (NT-proBNP) value has limited usefulness in diagnosing heart failure with preserved ejection fraction (HFpEF). Aim The aim of the present study is to evaluate serum Galectin-3 as a diagnostic biomarker in patients with HFpEF and to compare Galectin-3 with NT-proBNP levels. Materials and Methods A cross-sectional case–control study including 63 cases of heart failure with ejection fraction ≥50% confirmed by echocardiography. NT-proBNP levels in serum were measured by electrochemiluminescence immunoassay and Galectin-3 levels in serum were measured by using an enzyme-linked-immunosorbent serologic assay kit. Results The median levels of serum Galectin-3 and NT-proBNP in patients were significantly higher than those of controls (26.59 vs. 5.27 and 927 vs. 49.3, p < 0.0001). A positive correlation was observed between serum levels of Galection-3 and NT-ProBNP (r: 0.21, p = 0.048). At cut-off values of 10.1 ng/mL and 160 pg/mL, serum Galectin-3 has 77.78% sensitivity, 95% specificity with an area under the curve (AUC) of 0.93, and serum NT-proBNP has 71.43% sensitivity, 100% specificity with an AUC of 0.87, respectively, for diagnosing HFpEF. The comparison of receiver operating characteristics curves showed that Galectin-3 has better AUC compared with NT-proBNP in diagnosing HFpEF. Serum Galectin-3 showed a positive correlation with NT-proBNP and lipid parameters. Conclusion Galectin-3 with higher sensitivity and AUC can be used as a valuable biomarker for the diagnosis of HFpEF. Simultaneous testing of both Galectin-3 and NT-proBNP can further improve the detection of patients with HFpEF.

show abstract

Section: Discussionsupporting

confidence: 59%

Section: Discussionmentioning

confidence: 92%

Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the CORONA study, 1492 patients with heart failure caused by ischemic myocardiosis were randomly divided into a Rosuvastatin treatment group and a control group: the mortality of the statin group was lower than that of the control group and Gal-3 decreased significantly in the statin group [80]. Polat et al found that Gal-3 played an important role in prevention, classification, and personal therapy of heart failure [81]. Aforementioned studies revealed the clinical significance of Gal-3 in atherosclerosis-associated heart failure, but the mechanism of Gal-3 leading to heart failure needs to be further detected.…”

Section: Gal-3 and Heart Failurementioning

confidence: 99%

Galectin-3 Is a Potential Mediator for Atherosclerosis

Gao

Liu

Wang

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Atherosclerosis is a multifactorial chronic inflammatory arterial disease forming the pathological basis of many cardiovascular diseases such as coronary heart disease, heart failure, and stroke. Numerous studies have implicated inflammation as a key player in the initiation and progression of atherosclerosis. Galectin-3 (Gal-3) is a 30 kDa β-galactose, highly conserved and widely distributed intracellularly and extracellularly. Gal-3 has been demonstrated in recent years to be a novel inflammatory factor participating in the process of intravascular inflammation, lipid endocytosis, macrophage activation, cellular proliferation, monocyte chemotaxis, and cell adhesion. This review focuses on the role of Gal-3 in atherosclerosis and the mechanism involved and several classical Gal-3 agonists and antagonists in the current studies.

show abstract

“…It was demonstrated in animal models that galectin-3 contributes to the development and progression of heart failure through cardiac fibrosis and adverse structural remodeling [12]. Recent studies indicate that galectin-3 may reflect the presence of echocardiographically assessed heart failure with preserved ejection fraction (HFpEF) better than NT-proBNP due to a higher degree of cardiac fibrosis as a consequence of a chronically increased afterload during arterial hypertension [13–15]. Also galectin-3 was shown to correlate with LVEF in cMRI in patients after myocardial infarction [16] and to serve as a strong prognostic biomarker in chronic stages of heart failure [17–19].…”

Section: Introductionmentioning

confidence: 99%

Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging

et al. 2016

View full text Add to dashboard Cite

Background. This study investigates whether serum levels of galectin-3 may reflect impaired mitral annular plane systolic excursion (MAPSE) in patients undergoing cardiac magnetic resonance imaging (cMRI). Methods. Patients undergoing cMRI during routine clinical care were included prospectively within an all-comers design. Blood samples for biomarker measurements were collected within 24 hours following cMRI. Statistical analyses were performed in all patients and in three subgroups according to MAPSE (MAPSE I: ≥11 mm, MAPSE II: ≥8 mm–<11 mm, and MAPSE III: <8 mm). Patients with right ventricular dysfunction (<50%) were excluded. Results. 84 patients were included in the study. Median LVEF was 59% (IQR 51–64%). Galectin-3 correlated significantly with NT-proBNP (r = 0.42, p = 0.0001). Galectin-3 increased significantly according to the different stages of impaired MAPSE (p = 0.006) and was able to discriminate both patients with impaired MAPSE <11 mm (area under the curve (AUC) = 0.645, p = 0.024) and <8 mm (AUC = 0.733, p = 0.003). Combining galectin-3 with NT-proBNP improved discrimination of MAPSE <8 mm (AUC 0.803, p = 0.0001). In multivariable logistic regression models galectin-3 was still associated with impaired MAPSE (MAPSE < 11 mm: odds ratio (OR) = 3.53, p = 0.018; MAPSE < 8 mm: OR = 3.18, p = 0.06). Conclusions. Galectin-3 reflects MAPSE being assessed by cardiac MRI.

show abstract

Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction

Abstract: Our results support that, in addition to NT-proBNP, galectin-3 is also a valuable biomarker for the diagnosis of patients with HFpEF.

Cited by 29 publications

References 0 publications

Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction

Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction

Galectin-3 Is a Potential Mediator for Atherosclerosis

Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging

Contact Info

Product

Resources

About